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Epidemiology and Characteristics of Metallo-β-
Lactamase-Producing Pseudomonas aeruginosa
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Kyungwon Lee1
1Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul;  
2Department of Dental Hygiene, Silla University, Busan; 3Department of Biomedical Laboratory Science, College of Health Sciences, 
Sangji University, Wonju, Korea
Metallo-β-lactamase-producing Pseudomonas aeruginosa (MPPA) is an important nosocomial pathogen that shows resistance to 
all β-lactam antibiotics except monobactams. There are various types of metallo-β-lactamases (MBLs) in carbapenem-resistant P. 
aeruginosa including Imipenemase (IMP), Verona integron-encoded metallo-β-lactamase (VIM), Sao Paulo metallo-β-lactamase 
(SPM), Germany imipenemase (GIM), New Delhi metallo-β-lactamase (NDM), Florence imipenemase (FIM). Each MBL gene 
is located on specific genetic elements including integrons, transposons, plasmids, or on the chromosome, in which they carry 
genes encoding determinants of resistance to carbapenems and other antibiotics, conferring multidrug resistance to P. aerugino-
sa. In addition, these genetic elements are transferable to other Gram-negative species, increasing the antimicrobial resistance 
rate and complicating the treatment of infected patients. Therefore, it is essential to understand the epidemiology, resistance 
mechanism, and molecular characteristics of MPPA for infection control and prevention of a possible global health crisis. Here, 
we highlight the characteristics of MPPA.
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Review Article
Introduction  
The continuous emergence, worldwide spread, and increas-
ing prevalence of bacteria resistant to multiple antimicrobial 
agents are becoming major threats to public health [1-5]. Mul-
tidrug and pandrug resistant (MDR or PDR) bacterial infec-
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Resistance rate (%) Reference
or GenBank 
accession No.Carbapenem Imipenem Meropenem Doripenem Ertapenem
East Asia China 2003-2011 43.4 40.9 [70]
Japan 2013 28.5 22.8 12.5 [71]
Korea 2011 22 [61]
Taiwan 2003-2011 16 19 [72]
Southeast Asia Philippines 2010 31.1 [73]
Singapore 2010 23.3 [73]
Thailand 2010 28.7 [73]
Vietnam 2010 46.7 [73]
South Asia India 2011 32 [74]
Iran 2011-2012 31.8 13.5 74.4 [75]
North Asia Russia 2008-2010 75.3 [37]
Southwest Asia Israel 2009-2011 24.7 [76]
Saudi Arabia 2009-2010 56 34 [77]
Turkey 2009-2011 49.2 [76]
West Europe Belgium 2009-2011 41.1 [76]
France 2009-2011 18.2 [76]
Germany 2009-2011 24.4 [76]
Greece 2011 50.0 [78]
Ireland 2009-2011 13.8 [76]
Italy 2009-2011 19.9 [76]
Portugal 2009-2011 35.6 [76]
Spain 2009-2011 21.0 [76]
Switzerland 2009-2011 21.7 [76]
North Europe Poland 2009-2011 70.7 [76]
Sweden 2009-2011 10.9 [76]
Oceania Australia 2011 16 [74]
New Zealand 2010 10.3 [73]
North Africa Algeria 2009-2012 39.3 [79]
East Africa Kenya 2006-2007 13.7 [80]
South Africa South Africa 2006 45 42 [81]
North America Canada 2009-2010 3.3 [82]
Mexico 2005-2010 22 [83]
US 2012-2013 20 [84]
Central America Costa Rica Unavailable 63.1 [85]
Dominica Republic 2010 8 8 [86]
El Salvador 2010 25 24 [86]
Guatemala 2010 36 34 [86]
Honduras 2010 20 [86]
Nicaragua 2010 32 40 [86]
Panama 2010 34 23 [86]
South America Argentina 2010 33 37 [86]
Bolivia 2010 20 14 [86]
Brazil 2005 37-57 36-52 [86]
Chile 2005 32-40 30-33 [86]
Columbia 2010 17 19 [86]
Ecuador 2010 21 27 [86]
Paraguay 2010 30 30 [86]
Peru 2010 66 57 [86]
Uruguay 2010 35 43 [86]
Venezuela 2010 33 [86]
aCountries are listed in alphabetical order.
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tions are closely associated with high mortality, prolonged 
hospitalization, multiple morbidities, and increased cost due 
to the limited antimicrobial therapeutic options for infected 
patients [6, 7]. Pseudomonas aeruginosa is one of the primary 
opportunistic pathogen that causes a variety of nosocomial 
infections including sepsis, pneumonia, urinary tract infec-
tion, and soft-tissue infection [8]. This species is frequently 
isolated from immunocompromised patients who underwent 
organ transplantation, invasive procedure, immunosuppres-
sive therapy, or intensive care [9-11]. 
P. aeruginosa is one of the most important bacteria with doc-
umented resistance to multiple antimicrobial classes including 
β-lactams, carbapenems, aminoglycosides, fluoroquinolones, 
and polymyxins [12, 13]. Due to its intrinsic and acquired anti-
microbial resistance, only limited classes of antibiotics are ef-
fective for the treatment of P. aeruginosa infections. Among 
these antibiotics, carbapenems have been regarded as the most 
potent β-lactams against MDR Gram-negative bacilli including 
P. aeruginosa due to their high affinity with penicillin-binding 
proteins, stability against extended-spectrum β-lactamases (ES-
BLs), and permeability of bacterial outer membranes [14]. Re-
sistance to carbapenems is particularly challenging in clinical 
settings because they are the mainstays for treatment of multi-
drug resistance P. aeruginosa. There are few remaining antibi-
otic options for this strain, and multidrug resistance is much 
more common for patients infected with carbapenem-resistant 
P. aeruginosa [6, 15, 16]. 
Among the various antimicrobial resistance mechanisms, 
the production of carbapenemase is one of the most import-
ant mechanisms by which P. aeruginosa acquires carbapen-
em resistance. Many carbapenemases have been identified in 
P. aeruginosa, including (1) KPC and GES variants of Ambler 
class A, (2) IMP-, VIM-, SPM-, GIM-, NDM-, and FIM-type 
metallo-β-lactamases (MBLs) of Ambler class B, and (3) OXA 
variant enzymes of Ambler class D [17-25].
Here, we overview the epidemiology and molecular charac-
teristics of metallo-β-lactamase-producing P. aeruginosa 
(MPPA).
 Epidemiology of carbapenem-resistant  
P. aeruginosa
The global epidemiology of carbapenem-resistant P. aerugi-
nosa (CRPA) was analyzed based on a careful and thorough 
literature search of http://www.ncbi.nlm.nih.gov/pubmed 
with the combination of key words including the name of 
each nation, carbapenem, P. aeruginosa, MBL, epidemiology, 
prevalence, Gram-negative, national survey, and resistance. 
Countries were grouped by continent in order to show inter-
national differences in CRPA prevalence related to geographi-
Figure 1. Geographical distribution of carbapenem-resistant Pseudomonas aeruginosa. Most isolates were collected from 2009 to 2011 with 
the following exceptions: Chile (2005), Kenya (2006 to 2007), and South Africa (2006). The white colored areas indicate that there was no 
available published data for that region.
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Table 2. Imipenemase-type metallo-ß-lactamases found in Pseudomonas aeruginosa 
IMP variant
Frequently identified  
sequence types
Country of isolation





IMP‐1 175, 186, 235, 244, 277, 308, 360, 357, 
593, 645, 964, 1,015, 1,070, 1,162
Japan C1I  [38, 87]
South Korea C1I [63]
Brazil Unknown  [23]
China Unknown  [88]




IMP‐2 NR Japan C1I  [93]
IMP‐4 NR Malaysia Unknown [94]
Australia C1I [95]
China C1I [96]
IMP‐5 NR Portugal C1I  [97]
IMP‐6 235, 244, 591, 744, 745, 1,015, 1,162 South Korea C1I [98]
China Unknown [99]





Czech Republic C1I [104]
Denmark Unknown [105]
IMP‐8 308 Germany C1I  [43]
IMP‐9 NR China C1I [106]
Malaysia C1I  [107]
IMP‐10 NR Japan C1I [108]
China C1I [109]
IMP‐11 NR Japan Unknown AB074437
IMP‐13 111, 308, 621 Austria C1I [110]
Italy C1I [111]
France C1I [112]
Belgium C1I  [113]
IMP‐14 260 Thailand C1I [114]
IMP‐15 606, 654, 1,446 Mexico C1I [115]
Spain C1I  [116]
Germany Unknown  [76]
IMP‐16 NR Brazil C1I  [117]
IMP‐18 NR USA Unknown [118]
Mexico C1I [119]
Puerto Rico C1I  [120]
IMP‐19 235 Japan Unknown AB184876
Italy C1I [121]
IMP‐20 NR Japan C1I AB196988
IMP‐21 NR Japan C1I AB204557
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cal distance. We found published reports from a total of 50 
countries regarding country of isolation and collection period 
of clinical isolates, as well as the ratio of CRPA to all P. aerugi-
nosa (Table 1).
In most countries, the reported CRPA ratio ranged from 10 
to 50%. The carbapenem resistance rates in Canada (carbape-
nem 3.3%) and the Dominican Republic (imipenem and 
meropenem, both 8%) were the lowest of all countries, with 
ratios lower than 10%. On the other hand, ratios in Brazil, 
Peru, Costa Rica, Russia, Greece, Poland, Iran, and Saudi Ara-
bia were higher than 50% in all drugs of the carbapenem class 
(imipenem, meropenem, doripenem, ertapenem) ranging 
from 50% to 75.3% (Fig. 1). As shown in Figure 1, Russia, 
Southwest Asia, and South America were the predominant ar-
eas with antimicrobial resistance rates high enough to cause 
concern for public health to microbiologists and infection 
specialists.
The geographical distribution and ratio of CRPA differed 
from country to country; many CRPA strains have been identi-
fied and their prevalence is increasing gradually. The world-
wide emergence of carbepenem-resistant strains with similar 
mobile genetic elements indicates the dissemination of genes 
encoding carbapenemases through horizontal gene transfer 
[26]. The increase in CRPA ratio is known to be driven by both 
carbapenem use and the application of medical devices, 
which prompt the selection of resistant organisms [27]. Both 
factors are related to patient characteristics and clinical prac-
tice policies and/or antibiotic prescription patterns of health 
care facilities in each country.
Resistance mechanisms to carbapenem can be categorized 
into (1) deficiency of the outer membrane porin OprD, (2) 
bacterial production of carbapenemases, or (3) overexpres-
sion of efflux pump [28-32]. Carbapenem resistance in P. 
aeruginosa is most often associated with OprD deficiency 
and less frequently with the release of carbapenemase by the 
pathogen [33-35].
 Carbapenemases from each β-lactamase Ambler class have 
been identified in P. aeruginosa. Of these, Ambler class B 
β-lactamases are the most clinically significant carbapene-
mases and are called metallo-β-lactamase (MBL) because a 
metal ion, such as Zn2+, is essential for their activity, which can 
be inhibited by metal ion chelators.
Types of metallo-β-lactamases in P. aeruginosa
MBLs efficiently hydrolyze carbapenems and other 
β-lactams (except monobactams) and are not inhibited by the 
clinically available β-lactamase inhibitors including clavulanic 
IMP variant
Frequently identified  
sequence types
Country of isolation





IMP‐22 175, 620 Austria C1I [110]
Italy C1I  [122]
IMP‐25 China C1I EU352796
IMP‐26 235, 654 Malaysia C1I  [123]
Singapore Unknown [31]
IMP‐29 235 France C1I  [124]
IMP‐30 NR Russia Unknown [125]
IMP‐31 235 Germany Unknown [126]
IMP‐33 NR Italy C1I [127]
IMP‐35 622 Germany C1I  [128]
IMP‐37 111, 308, 621 France Unknown JX131372
IMP‐40 NR Japan Unknown AB753457
IMP‐41 NR Japan Unknown AB753458
IMP‐43 235, 357 Japan C1I  [129]
IMP‐44 357 Japan C1I  [129]
IMP‐45 308 China C1I  [130]
IMP‐48 NR USA Unknown KM087857
IMP, imipenemase; C1I, Class 1 integron; NR, not reported.
Table 2. Continued
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Table 3. Verona integron-encoded metallo-ß-lactamases found in Pseudomonas aeruginosa 
VIM type MBL






or GenBank  
accession No.
VIM‐1 17, 111, 227, 228, 235 Italy C1I [39]
France C1I [131]
Greece C1I [132]
Germany Unknown  [76]
Italy C1I [121]
VIM‐2 17, 111, 155, 175, 179, 229, 233, 235, 244, 
309, 364, 639, 640, 654, 773, 811, 973, 
1,020, 1,074, 1,699, 1,700




India Unknown  [134]
Kenya Unknown  [80]
Hungary C1I  [135]
Malaysia C1I  [136]













Belgium Unknown  [76]
Germany Unknown  [76]
Turkey Unknown  [76]
Egypt C1I [145]
VIM‐3 298 Taiwan Unknown [146]
VIM‐4 111, 229, 230, 235, 313 Greece C1I [44]
Sweden Unknown [44]
Poland C1I [44]
Hungary C1I  [135, 147]
France Unknown  [76]
VIM‐5 85, 534 India Unknown  [134]
Turkey C1I [44]
VIM‐6 85, 746 India C1I  [134]
Indonesia C1I [148]
South Korea C1I [148]
Philippines C1I [148]
VIM‐7 NR USA C1I [149]
VIM‐8 NR Columbia Unknown  [150]
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acid or tazobactam. Except for the SPM-type enzymes, most 
MBL genes reside within various compositions of integron 
gene cassettes that are encoded on genes linked to mobile el-
ements, which is a condition that facilitates their spread 
among different bacterial species and genera through hori-
zontal gene transfer [36, 37]. The most notable of the acquired 
MLBs, the IMP- and VIM-type enzymes, were first detected in 
the early 1990s [38, 39]. Thereafter, many additional types of 
acquired MBLs have been reported, including the SPM-, GIM-, 
SIM-, KHM-, NDM-, AIM-, DIM-, SMB-, TMB-, and FIM-type 
enzymes [40, 41]. Since the discovery of IMP-1, which was the 
first MBL identified in P. aeruginosa, IMP-, VIM-, SPM-, GIM-, 
NDM- and FIM-type variants in P. aeruginosa have been re-
ported steadily.
Imipenemase (IMP)
In 1988, transferable IMP-1 was first isolated from P. aerugi-
nosa in Japan [38] and was found in a class 1 integron located 
on a conjugational plasmid. Thereafter, it was identified in 
many other species suggesting horizontal gene transfer of 
blaIMP-1 between unrelated Gram-negative species, and also 
showed predominance of specific IMP type-producing iso-
lates demonstrating clonal expansion [15]. Currently 33 of the 
51 known IMP variants have been identified from P. aerugi-
nosa, including the recent detection of IMP-8-producing 
strains in Germany [42, 43] (Table 2). IMP-like enzymes are 
divided into several subgroups, and the percentage amino 
acid identity within these subgroups ranges from 90% to 99% 
showing very similar hydrolytic activities among them [44]. 
Verona integron-encoded metallo-β-lactamase 
(VIM)
VIM enzymes share the same hydrolytic spectrum the IMP-
type enzymes, with less than 40% amino acid identity [45]. 
VIM-1 was identified first in P. aeruginosa in 1999, and after 
that, has also been reported in other Gram-negative species 
from several countries [39]. Currently, VIM-2 is the most wide-
spread MBL in P. aeruginosa and has been the source of mul-
tiple outbreaks [44]. Twenty-four of the 46 VIM variants, in-
cluding VIM-43 found in the USA (GenBank accession 
VIM type MBL






or GenBank  
accession No.
VIM‐9 NR UK Unknown AY524988
VIM‐10 NR UK Unknown  [151]
VIM‐11 NR India C1I  [134]
Argentina Unknown  [152]
Italy Unknown AY635904
Malaysia C1I  [136]
VIM‐13 235 Spain C1I  [153]
VIM‐14 260 Spain Unknown EF055455
Italy C1I  [154]
VIM‐15 NR Bulgaria C1I [155]
VIM‐16 NR Germany C1I [155]
VIM‐17 NR Greece C1I [156]
VIM‐18 NR India C1I  [134]
VIM‐20 NR Spain Unknown  [157]
VIM‐28 NR Egypt C1I [158]
VIM‐30 NR France C1I JN129451
VIM‐36 111 Belgium Unknown  [76]
VIM‐37 NR Poland Unknown  [76]
VIM‐38 NR Turkey C1I  [159]
VIM‐43 NR USA Unknown KP096412
VIM, Verona-integron-encoded metallo-ß-lactamase; MBL, metallo-β-lactamase; C1I, Class 1 integron; NR, not reported.
Table 3. Continued
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number KP096412), have been identified in P. aeruginosa 
(Table 3).
Sao Paulo metallo-β-lactamase (SPM)
SPM-1 was first isolated in Brazil in 1997 from a P. aerugino-
sa clinical isolate that was resistant to all available antibiotics 
except colistin [46] (Table 4). SPM is quite different from VIM 
and IMP, presenting the highest amino acid identity to IMP-1 
(35.5%), and represents a new subfamily of MBLs. Dissemina-
tion of MDR P. aeruginosa producing SPM-1 was demonstrat-
ed in distinct regions of Brazil; however, these strains have not 
yet spread to other countries, with only one exception of a sin-
gle isolate identified in a Swiss patient who had previously 
been hospitalized in Brazil [47, 48]. The blaSPM-1 gene has been 
reported in Pseudomonas and Acinetobacter spp. isolated 
from various hospitals in Brazil, and its product is a major 
contributor to the high level carbapenem resistance observed 
in South America. Currently, the ratio of carbapenem resis-
tance in South America is among the highest in the world [49]. 
The blaSPM-1 gene is either chromosomal or plasmid-encoded. 
In addition, it is associated with the insertion sequence com-
mon region 4 (ISCR4) at the origin of its acquisition and ex-
pression and is likely transposed through a rolling-circle repli-
cation mechanism [50].
Germany imipenemase (GIM)
In 2002, GIM-1 was identified in P. aeruginosa isolates from 
Germany (Table 4). Molecular analysis revealed that the ami-
no acid sequence identity of GIM-1 with other clinically signif-
icant MBL genes, including IMP and VIM variants, was less 
than 45%, indicating that GIM-1 is a new phylogenetic sub-
class of MBLs. Initially, this enzyme was not predicted to be 
mobile because the 22-kb plasmid carrying In77 is nonconju-
gative and has a restricted host range [51]; however, GIM-1 
has also been found in Enterobacter cloacae, Pseudomonas 
putida, Serratia marcescens, Escherichia coli, Klebsiella oxy-
toca, and Citrobacter freundii [52]. Molecular analysis of class 
1 integron arrays showed that most blaGIM-1 gene cassettes 
shared identical elements (aacA4, aadA1, and blaOXA-2), which 
demonstrates horizontal gene transfer of a large block of ge-
netic information [52]. To date, there have been no reports of 
GIM-1-producing strains outside of Germany.
New Delhi metallo-β-lactamase (NDM)
NDM-1 was first isolated in Klebsiella pneumoniae and 
Escherichia coli recovered from a patient who was previously 
admitted to a hospital in New Delhi, India, in 2009 [53]. Since 
then, additional six NDM variants (NDM-2 to NDM-7) have 
been identified in P. aeruginosa, Acinetobacter baumannii, 
and E. coli. NDM-1-producing P. aeruginosa strains were first 
reported in 2011, with two isolates recovered from Serbia [20] 
(Table 4). In 2012, NDM-1-producing P. aeruginosa sequence 
type 235 (ST235) strain was isolated in France from a patient 
previously hospitalized in Serbia [54, 55]. Since then, 
NDM-1-positive P. aeruginosa isolates have been recovered 
throughout the world including India, Italy, Egypt, and Slova-
kia [56-59].








NDM-1 235 Serbia Chromosome  [20]
France Chromosome  [54, 55]
India Plasmid [56]
Italy Chromosome  [57]
Egypt Unknown  [58]
Slovakia Unknown [59]
SPM-1 NR Brazil ISCR4 [160]
Switzerland ISCR4 [48]
GIM-1 NR Germany Class 1 Integron, Plasmid  [51, 52]
FIM-1 235 Italy Chromosome  [60]
MBL, metallo-β-lactamase; NDM, New Delhi metallo-ß-lactamase; SPM, Sao Paulo metallo-ß-lactamase; NR, not reported; ISCR4, insertion sequence common region 4; 
GIM, Germany imipenemase; FIM, Florence imipenemase.
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Florence imipenemase (FIM-1)
In 2012, a novel FIM-1 MBL was isolated from a MDR P. 
aeruginosa in Florence (Italy) that showed highest similarity 
(40% amino acid identity) with NDM-type enzymes [60] (Ta-
ble 4). This isolate belonged to the ST235 epidemic clonal lin-
eage. Anaylsis of the kinetic parameters showed that FIM-1 
has a broad substrate specificity, especially with penicillins 
and carbapenems. The blaFIM-1 gene was chromosomally lo-
cated and was associated with ISCR19-like elements that were 
likely involved in its capture and mobilization; its origin re-
mains unknown [60].
Metallo-β-lactamase-producing P. aeruginosa in 
Korea
VIM-2 was first described in P. aeruginosa isolated from the 
blood culture of a woman treated with imipenem in Mar-
seilles, France, in 1996 [62]. The first reported MBL in Korea 
was a VIM-2-producing P. aeruginosa isolated in 2002 [19]. 
Since then, many MBL enzymes including VIM-2 have been 
detected in P. aeruginosa, Acinetobacter spp., and Enterobac-
teriaceae isolates. The prevalence of dominant MBL types has 
changed with time. In 2003, more than 10% of imipenem-re-
sistant P. aeruginosa produced VIM-2 type MBL, but the ratio 
of VIM-2 carriage decreased to 7.7% according to a study in 
2005, which was followed by IMP-1 at 2.4% and IMP-6 at 0.7% 
[63-65]. In 2011, the ratio of imipenem-resistant P. aeruginosa 
was 22% among 15,032 clinical isolates in Korea, and IMP-6 
became the dominant MBL enzyme in Korea, representing 
7.8% of all P. aeruginosa clinical isolates, followed by VIM-2 at 
0.3% [66]. This trend in MPPA was also found in 2015; al-
though the prevalence of MPPA in P. aeruginosa clinical iso-
lates slightly decreased from 8.0% (31/386) to 6.4% (21/329), 
IMP-6 was still the most frequently detected MBL type in P. 
aeruginosa in Korea, followed by VIM-2 at 1.2% (4/329), 
which is different from the worldwide prevalence of VIM-2 
[66-68]. IMP-6 was first identified in Japan in 1996 in plasmid 
pKU501 from Serratia marcescens KU383. It showed very 
similar amino acid identity with IMP-1 MBL, differing by only 
one Ser196Gly amino acid substitution, resulting in augment-
ed hydrolytic activity for meropenem [69].
Molecular analysis demonstrated that ST235 is the most 
dominant MPPA in Korea [67]. Association of ST235-like 
strains with MBL genes has been reported in several Europe-
an countries, with VIM-1-producers in Italy; VIM-4-producers 
in Greece, Sweden, Hungary and Belgium; VIM-13-producers 
in Spain; and IMP-29-producers in France [42]. This clone 
might therefore possess some specific traits enhancing its clon-
al dissemination. The combination of prevalent sequence types 
and specific MBL enzymes might suggest the keys to under-
stand the proliferation of resistant strains and mechanisms of 
gene transfer. Given that MPPA ST235 was the only strain de-
tected in Korea five years ago, it is also worthy to note that 
MPPA ST309 and ST463 have emerged along with the prevalent 
MPPA ST235 strain because this clonal diversity might be a sign 
of alarm for additional dissemination of MPPA in Korea. 
Conclusion
The emergence and dissemination of MPPA is a global con-
cern threatening not only immunocompromised patients, but 
also healthy members of the community. MPPA is an import-
ant bacteria due to the antimicrobial resistance characteristics 
as well as its pathogenicity. It contains multiple antimicrobial 
resistance genes and has the potential to transfer these to oth-
er strains, which is a major clinical problem because of limited 
treatment options for patients infected with MPPA. There are 
many obstacles to overcome regarding bacterial resistance. 
These can be broadly categorized into issues of emergence, 
spread, and clonal expansion with diversity. These factors are 
related to each other and are very difficult to control. Several 
factors are already well known to cause the proliferation of re-
sistant strains, which include natural genetic diversification 
caused by mutation, horizontal gene transfer among other spe-
cies, an increase of international travel and patient transfer be-
tween countries raising the possibility for further dissemination 
of resistant strains, and greater antibiotic selective pressure es-
pecially in immunocompromised patients who received ag-
gressive and invasive treatment. Further studies on epidemiolo-
gy, antimicrobial resistance mechanisms, proper antibiotic 
stewardship, and rapid diagnostic methods for detection of 
MPPA are recommended in order to develop strategies that 
contain the dissemination and limit the transmission of MPPA.
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